<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2012</study_start_year><condition>Metastatic Colorectal Cancer</condition><condition>Colorectal Neoplasms</condition><disease>Metastatic Colorectal Cancer</disease><disease>Colorectal Neoplasms</disease><study_type>Observational patient registry</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2145309</full_dataset_link><location>China</location><study_start_month>6</study_start_month><keyword>Adverse events</keyword><keyword>Overall survival</keyword><keyword>Tumor resection rate</keyword><keyword>Bevacizumab</keyword><repository>ECRIN MDR</repository><study_status>Not provided</study_status></additional><is_claimable>false</is_claimable><name>An Observational Study of Bevacizumab in Chinese Patients With Metastatic Colorectal Cancer</name><description>This observational, multicenter, prospective study will evaluate the use of bevacizumab in real clinical practice in chinese patients with metastatic colorectal cancer.</description><dates><creation>2012-06-15</creation></dates><accession>2145309</accession><cross_references><ClinicalTrials___gov>NCT01860144</ClinicalTrials___gov></cross_references></HashMap>